• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Fracture - Pipeline Review, Q4 2010 - Product Image

Fracture - Pipeline Review, Q4 2010

  • ID: 1474183
  • December 2010
  • 45 pages
  • Global Markets Direct

Fracture - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Fracture    Pipeline Review, Q4 2010”, provides an overview of the Fracture    therapeutic pipeline. This report provides information on the therapeutic development for Fracture   , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fracture   . “Fracture   -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Fracture   .
- A review of the Fracture    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fracture Overview
Therapeutics Development
An Overview of Pipeline Products for Fracture
Fracture Therapeutics under Development by Companies
Fracture Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Fracture Therapeutics Development
Baxter International Inc.
Amgen Inc.
Eli Lilly and Company
Daewoong Pharmaceutical Co., Ltd.
GTx, Inc.
Zelos Therapeutics, Inc.
Geron Corporation
Kaken Pharmaceutical Co.,Ltd.
Ligand Pharmaceuticals Incorporated
Universities/Institutes Involved in Fracture Therapeutics Development
Fracture Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Acapodene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
B-FGF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
cholecalciferol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tranexamic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fracture - Featured News
Jun 08, 2010: GTx Announces Toremifene 80mg Treatment Demonstrated Improved Fracture Reduction And Safety Profile In Men With Prostate Cancer On ADT Younger Than Age 80
Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures
May 30, 2010: GTx Announces Upcoming Presentation Of Additional Study Results From Phase III Clinical Trial Of Toremifene 80mg
Jun 10, 2008: Kuros Starts Phase IIb Clinical Trial With KUR-113 In Open Tibial Fractures
Apr 16, 2008: Zelos Therapeutics and Aegis Therapeutics Announce Collaboration for Intranasal Delivery of Zelos’ ZT-031
Oct 18, 2007: Aastrom Stem Cell Therapy Demonstrates Positive Results In Severe Long Bone Non-Union Fracture Trial
Feb 16, 2007: OrthoLogic Announces Results Of Post Hoc Subgroup Analysis Of Data From Phase 3 Clinical Trial Of Chrysalin (TP508) In Fracture Repair
Aug 29, 2006: OrthoLogic Announces Results Of Preliminary Interim Analysis Of Phase 2b Clinical Trial Of Chrysalin (TP508) In Fracture Repair
May 27, 2002: Celltech Amgen Enter Osteoporosis Deal
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos